Membranoproliferative glomerulonephritis (MPGN) is a group of diseases characterized by changes in the structure of the glomeruli of the kidneys. It is an organ-specific inflammatory disease in which mesangial and podocyte cells proliferate, and immune complexes are deposited in the capillary wall. The main clinical manifestation of MPGN is the symptoms of nephritic syndrome, such as edema, hypertension, and proteinuria. Progression of the disease can lead to acute or chronic renal failure, making it a clinically significant condition. Classification is usually based on morphological and clinical features, which allows for the establishment of an appropriate therapeutic approach and prognosis for the patient.
History of the disease and interesting historical facts
Membranoproliferative glomerulonephritis was first described in the 1950s. The need for a deeper understanding of the disease arose against the background of an increase in cases of acute and chronic kidney damage, which contributed to the development of histological research methods. One of the first scientists to systematize data on MPGN was A.S. Grunwald, who in 1957 identified it as a separate nosological unit, describing pathomorphological changes observed in the kidneys. Since then, significant progress has been made in the study of this disease, and modern diagnostic and treatment methods have begun to be used in clinical practice.
Epidemiology
According to various studies, the prevalence of membranoproliferative glomerulonephritis varies. The disease most often occurs in people aged 20 to 40 years. According to statistics, the incidence of MPGN is approximately 2-5 cases per 100,000 population annually. In some regions with a high incidence of pneumonia and other infections, there may be an increase in MPGN cases, which may be associated with infectious agents that serve as triggers for the development of this pathology. It is important to note that the disease occurs more often in men than in women.
Genetic predisposition to this disease
Research suggests that some patients with membranoproliferative glomerulonephritis have a genetic predisposition, including mutations in certain genes. Known genes involved in the pathogenesis of the disease include:
- Gene C3 (encodes complement component 3)
- CFH gene (encodes complement factor H)
- MCP gene (encodes membrane cofactor protein)
Mutations in these genes can lead to a disruption of complement regulation, which in turn can initiate pathological processes in the kidneys. In addition, other genetic factors are known that can influence the risk of developing MPGN, but their influence still requires further research.
Risk factors for the development of this disease
Risk factors for the development of membranoproliferative glomerulonephritis can be divided into several categories:
- Infectious agents (eg, hepatitis C and B viruses, some forms of infectious mononucleosis).
- Chemical influences (use of certain medications such as nonsteroidal anti-inflammatory drugs).
- Immune disorders (autoimmune diseases such as systemic lupus erythematosus).
- Environmental factors (environmental pollution, exposure to heavy metals).
These factors may contribute to the development of MPGN by interacting with the patient's genetic predisposition.
Diagnosis of this disease
Diagnosis of membranoproliferative glomerulonephritis involves the use of various approaches and techniques:
- The main symptoms are edema, proteinuria, sometimes hematuria and arterial hypertension.
- Laboratory tests of blood and urine to assess the level of creatinine and protein in the urine.
- Radiological examinations, including ultrasound examination of the kidneys to determine their size and structure.
- A kidney biopsy, which allows for a morphological analysis and a definitive diagnosis.
- Differential diagnosis with other forms of glomerulonephritis and nephrotic syndrome.
Establishing an accurate diagnosis is critical for choosing an effective treatment method and predicting the outcome of the disease.
Treatment
Treatment of membranoproliferative glomerulonephritis should be individualized based on disease severity and clinical manifestations. General strategies may include:
- Pharmacological treatment includes corticosteroids and immunosuppressants to control the inflammatory process.
- Antihypertensive drugs for regulating blood pressure.
- Diet therapy, which involves reducing the consumption of salt and protein.
- Hemodialysis or peritoneal dialysis in the development of renal failure.
- Surgical interventions in rare cases, for example, when a kidney transplant is needed.
The use of an integrated approach can significantly improve patient outcomes and quality of life.
List of medications used to treat this disease
Medications used for membranoproliferative glomerulonephritis include:
- Prednisolone
- Cyclophosphamide
- Mycophenolate mofetil
- Siolimus
- ACE inhibitors (eg, Enalapril)
Each of the above mentioned medications requires careful prescription and supervision by a physician.
Disease monitoring
Monitoring of the condition of patients with membranoproliferative glomerulonephritis includes:
- Regular laboratory tests to monitor urine protein levels and kidney function (creatinine, electrolytes).
- Monitoring of blood pressure and other clinical symptoms.
- Periodic ultrasound examinations of the kidneys to assess their condition.
- Evaluation of the clinical response to treatment, including, if necessary, changes in the therapeutic strategy.
- Prognosis depends on the form of MPGN, the degree of pathology and the adequacy of therapy.
Complications may include progressive kidney failure and cardiovascular disease.
Age-related features of the disease
Membranoproliferative glomerulonephritis can manifest itself in different ways depending on the patient's age:
- In children, the disease can be acute, often with a predominance of nephrotic syndrome.
- Chronic forms with linear proteinuria are more often observed in young and middle-aged people.
- Elderly patients may experience ease of diagnosis due to association with other pathologies such as diabetes mellitus and hypertension.
Thus, understanding age-related characteristics allows for a more effective approach to the diagnosis and treatment of the disease.
Questions and Answers
- What are the main signs of membranoproliferative glomerulonephritis? The main signs include edema, proteinuria, hypertension and possible hematuria.
- How is membranoproliferative glomerulonephritis treated? Treatment includes pharmacological therapy, symptom control and, in severe cases, dialysis or kidney transplant.
- What factors can contribute to the development of the disease? Infections, immune disorders, genetic predisposition, and exposure to chemicals are the main risk factors.
- What is the role of biopsy in the diagnosis of MPGN? A kidney biopsy provides the morphological basis for establishing an accurate diagnosis and determining the necessary treatment.
- How often should disease monitoring be performed? Monitoring is recommended to be performed regularly, with a frequency depending on the severity of the disease and the response to treatment.
